首页> 美国卫生研究院文献>Indian Journal of Virology >Pharmacophore modeling atom based 3D-QSAR and Molecular docking approaches to screen C-X-C chemokine receptor type 4 antagonists as microbicides for human immunodeficiency virus-1
【2h】

Pharmacophore modeling atom based 3D-QSAR and Molecular docking approaches to screen C-X-C chemokine receptor type 4 antagonists as microbicides for human immunodeficiency virus-1

机译:药理学建模基于原子的3D-QSAR和分子对接方法筛选C-X-C趋化因子受体4型拮抗剂作为人类免疫缺陷病毒1的杀微生物剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The C-X-C chemokine receptor type 4 receptor CXCR4 which acts as a co-receptor for human immunodeficiency virus-1, expressed in the later stages of infection is considered as an attractive and new target for drug design. Microbicides acting as co-receptor blockers are highly significant as these drugs block HIV lifecycle at early stage itself. The urgent need for a safe and effective microbicide urges to explore new CXCR4 antagonists which could be developed as microbicides. The pharmacophore based 3D-QSAR models and docking models were developed using PHASE and GLIDE modules of Schrodinger software. Three-dimensional quantitative structure–activity relationships (3D-QSAR) studies and pharmacophore modelling was carried out on a dataset of 114 CXCR4 antagonists with the intention of exploring entry inhibitors with better therapeutic potential. A training set of 43 compounds was used to create 3D-QSAR models and they were validated using a test set of 28 compounds. CXCR4 antagonists with good inhibitory activity could be designed and structurally modified based upon the QSAR model developed with necessary pharmacophore features. The results revealed that the common pharmacophore hypothesis ADHPR.1 was used for 3D-QSAR model development and the most active compound, CXCR4 antagonist no.44 which is a imidazopyridine-tetrahydro-8-quinolinamine derivative interacted with the CXCR4 receptor residue ASP 97 by the formation of a hydrogen bond. Also, the docking studies were carried out for the dataset for analyzing the binding conformation of CXCR4 and 114 antagonists. The results obtained from the 3D-QSAR studies and docking simulation can be used for designing new and potent CXCR4 antagonists. The compound identified from this study can be taken up further for validation by in vitro/in vivo studies.Electronic supplementary materialThe online version of this article (doi:10.1007/s13337-017-0397-1) contains supplementary material, which is available to authorized users.
机译:在感染后期表达的C-X-C趋化因子受体4型受体CXCR4充当人类免疫缺陷病毒-1的共受体,被认为是有吸引力的药物设计新目标。杀微生物剂作为共受体阻滞剂非常重要,因为这些药物在早期阶段就可以阻断HIV的生命周期。迫切需要安全有效的杀菌剂,因此急需探索可以开发为杀菌剂的新型CXCR4拮抗剂。使用Schrodinger软件的PHASE和GLIDE模块开发了基于药效团的3D-QSAR模型和对接模型。对114种CXCR4拮抗剂的数据集进行了三维定量结构-活性关系(3D-QSAR)研究和药效团建模,旨在探索具有更好治疗潜力的进入抑制剂。使用43种化合物的训练集创建3D-QSAR模型,并使用28种化合物的测试集对它们进行了验证。具有良好抑制活性的CXCR4拮抗剂可以基于具有必要药效团特征的QSAR模型进行设计和结构修饰。结果表明,常用药效团假说ADHPR.1用于3D-QSAR模型开发,活性最高的化合物CXCR4拮抗剂第44号为咪唑并吡啶-四氢-8-喹啉胺衍生物与CXCR4受体残基ASP 97相互作用。氢键的形成。此外,对数据集进行了对接研究,以分析CXCR4和114种拮抗剂的结合构象。从3D-QSAR研究和对接模拟获得的结果可用于设计新型有效的CXCR4拮抗剂。从这项研究中鉴定出的化合物可以进一步用于体外/体内研究验证。电子补充材料本文的在线版本(doi:10.1007 / s13337-017-0397-1)包含补充材料,可用于授权用户。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号